MapLight Therapeutics, Inc. (MPLT)
6.93
+0.71
(+11.41%)
USD |
NASDAQ |
Nov 06, 16:00
7.59
+0.66
(+9.52%)
After-Hours: 20:00
MapLight Therapeutics Research and Development Expense (Quarterly) : 53.44M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.44M |
| March 31, 2026 | 53.68M |
| December 31, 2025 | 64.62M |
| September 30, 2025 | 26.96M |
| June 30, 2025 | 26.71M |
| Date | Value |
|---|---|
| March 31, 2025 | 19.79M |
| June 30, 2024 | 15.47M |
| March 31, 2024 | 15.20M |
| March 31, 2023 | 10.42M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cullinan Therapeutics, Inc. | 44.44M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |
| Sarepta Therapeutics, Inc. | 82.55M |